RDPAC outlines ways to improve clinical research in China

China's R&D-based Pharmaceutical Association Committee proposed guidelines to improve the country's clinical research system, including the implementation of a top-down design that provides management and policy support at the national level.

Clinical research could increasingly become a bottleneck for drug development in China as more companies

Read the full 453 word article

User Sign In